Biotech Investment Analyst — Rubric & AI Evaluation

HumanitApp; Northern (KY); Hybrid; USD 165,000 - 276,000; Full time

Job summary

Mercor is seeking a US-based biotech investment analyst with a specialist-fund background to create and critique rubrics for evaluating commercial drugs and drug-development programs.

The engagement is a paid pilot (10–20 hours over 1–2 weeks), remote, with potential for ongoing work and strong contributors. You will assess assets and company profiles end-to-end and flag weak or unsubstantiated assumptions.

Qualifications

• US-based biotech/healthcare investment analyst with a specialist-fund background.
• Familiarity with biotech/pharma development programs.
• Able to assess a drug asset and the company behind it end-to-end.
• 5+ years evaluating biotech/pharma companies or assets.

Responsibilities

• Create and critique rubrics that analyze commercial drugs and drug-development programs.
• Provide overall company and asset assessment mechanism, clinical data, competitive position, and value drivers.
• Judge the quality of an investment-style thesis and flag weak, overconfident, or missing assumptions.
• Apply your assessment across the pilot's set of companies (~5–10).

Skills

Biotech investment analysis

Specialist fund background

Biotech/pharma development

Asset assessment end-to-end

Job description

Mercor is seeking a US-based biotech investment analyst with a specialist-fund background to create and critique rubrics for evaluating commercial drugs and drug-development programs.

The engagement is a paid pilot (10–20 hours over 1–2 weeks), remote, with potential for ongoing work and strong contributors. You will assess assets and company profiles end-to-end and flag weak or unsubstantiated assumptions.